Detalles de la búsqueda
1.
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
Cost Eff Resour Alloc;
21(1): 6, 2023 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36647072
2.
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
Lancet Oncol;
23(10): 1274-1286, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108662
3.
How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.
Infect Immun;
89(9): e0066520, 2021 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33526567
4.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
BMC Cancer;
21(1): 230, 2021 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33676426
5.
Lung cancer in Spanish women: The WORLD07 project.
Eur J Cancer Care (Engl);
28(1): e12941, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30277293
6.
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
BMC Cancer;
18(1): 106, 2018 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29382302
7.
Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07.
Cancer Invest;
35(5): 358-365, 2017 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350480
8.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Lancet Oncol;
16(8): 897-907, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26156651
9.
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.
Nature;
452(7187): 638-642, 2008 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-18385739
10.
Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity.
World J Oncol;
15(2): 223-238, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38545481
11.
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.
Clin Transl Oncol;
26(2): 352-362, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490262
12.
Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability.
Cancers (Basel);
16(6)2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539479
13.
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Clin Cancer Res;
2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630755
14.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Clin Transl Oncol;
2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38512450
15.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
N Engl J Med;
363(23): 2200-10, 2010 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-21121833
16.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol;
13(3): 239-46, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22285168
17.
[Risk factors for cancer-related cognitive impairment in breast and colorectal cancer patients who undergo chemotherapy].
An Sist Sanit Navar;
46(2)2023 Aug 16.
Artículo
en Español
| MEDLINE | ID: mdl-37594060
18.
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.
J Clin Med;
12(15)2023 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568465
19.
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Clin Transl Oncol;
25(1): 283-291, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36168085
20.
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Clin Transl Oncol;
25(5): 1252-1267, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36571695